EC Gastroenterology and Digestive System

Literature Article Volume 11 Issue 2 - 2024

Short Chain Fatty Acids in Intestinal Dysbiosis

Álvaro Zamudio Tiburcio1*, Héctor Bermúdez Ruiz2, Silverio Alonso López3 and Pedro Antonio Reyes López4

1Department of Gastroenterology, Intestinal Microbiota Transplantation Medical Specialties Naples Unit, Mexico
2Endoscopy Service, Oncology Hospital, National Medical Center, XXI Century, Mexican Social Security Institute, Hospital Trinidad, Mexico City, Mexico
3Department of Urologist, Chairman Medical Specialties Naples in Mexico City, Mexico
4Immunologist, Rheumatologist, National Institute of Cardiology “I. Chávez”, Mexico City, Mexico
*Corresponding Author: Álvaro Zamudio Tiburcio, Department of Gastroenterology, Intestinal Microbiota Transplantation Medical Specialties Naples Unit, Mexico.
Received: January 16, 2024; Published: January 29, 2024




We carried out an intense review of the functions of short chain fatty acids in intestinal dysbiosis and we were surprised to detect the utmost importance that exists in their daily impact on the processes of the digestive tract, as well as the extra-digestive ones.

We find the close relationship that exists between these acids, immunity, inflammation and metabolism. What predicts a successful future in its use, not only as a metabolic and immune complement, but as a therapeutic that can minimize the daily processes of chronic inflammation, which millions of human beings in the world experience.

All of this forces us to have these very current acids as priorities in our daily work and dedicate all the time possible to their development as possible antibiotics or as therapeutic sources.

We cannot ignore, when using short chain fatty acids, that patients have sufficient fiber intake, which can be used by multi-specific acids, as well as in parallel the use of diets, such as Paleo; without forgetting stress management, exercise and numerous actions harmful to the Intestinal Microbiome. Remembering the importance of controlling the intake of polyols and increasing polyphenols.

 Keywords: Short Chain Fatty Acids (SCFA); Intestinal Dysbiosis (ID); Gut Microbiota (GM); Inflammatory Bowel Disease (IBD)

  1. Dudeja PK and Ramaswamy K. “Intestinal anion absorption”. In physiology of the gastrointestinal tract (Fourth Edition) (2006).
  2. Kiela PR and Ghishan FK. “Physiology of intestinal absorption and secretion”. Best Practice and Research Clinical Gastroenterology 2 (2016): 145-159.
  3. Liu H., et al. “Butyrate: A double-edged sword for health?” Advances in Nutrition1 (2018): 21-29.
  4. Parada DV., et al. “Short chain fatty acids (SCFAs). Mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases”. Frontiers in Immunology 10(2019): 277.
  5. Tan J., et al. “The role of short-chain fatty acids in health and disease”. Advances in Immunology 121 (2014): 91-119.
  6. Tan C., et al. “Dysbiosis of gut microbiota and short-chain fatty acids in acute ischemic stroke and the subsequent risk for poor functional outcomes”. Journal of Parenteral and Enteral Nutrition 3 (2021): 518-529.
  7. Silva YP., et al. “The role of short-chain fatty acids from gut microbiota in gut-brain communication”. Frontiers in Endocrinology (Lausanne) 11 (2020): 25.
  8. Bravo JJ., et al. “Butyrate and colorectal carcinogenesis”. Cirugía Española1 (2000): 57-64.
  9. Hajjar R., et al. “The role of butyrate in surgical and oncological Outcomes in colorectal cancer”. American Journal of Physiology, Gastrointestinal and Liver Physiology4 (2021): G601-G608.
  10. Lu Y., et al. “Microbiota-derived short-Chain fatty acids: Implications for cardiovascular and metabolic diseases”. Frontiers in Cardiovascular Medicine 9 (2022): 900381.
  11. Chen J and Vitetta L. “Butyrate in inflammatory bowel diseases therapy”. Gastroenterology5 (2020): 1511-1513.
  12. Aden K., et al. “Metabolic functions of gut microbes associate with efficacy of tumor necrosis factor antagonists in patients with inflammatory bowel diseases”. Gastroenterology5 (2019): 1279-1292.e11.
  13. Yoshimatsu Y., et al. “Bacteriotherapy for inflammatory bowel disease”. Inflammation and Regeneration1 (2021): 3.
  14. Zhuang X., et al. “Fecal microbiota alterations associated with clinical and endoscopic response to infliximab therapy in Crohn’s disease”. Inflammatory Bowel Diseases 11 (2020): 1636-1647.
  15. Wan MLY., et al. “Probiotics interaction with foodborne Pathogens: a potential alternative to antibiotics and future challenges”. Critical Reviews in Food Science and Nutrition 20 (2019): 3320-3333.
  16. , et al. “Smectite promotes probiotic biofilm formation in the gut for cancer immunotherapy”. Cell Reports 34.6 (2021): 108706.
  17. Akhtar M., et al. “Gut microbiota-derived short chain fatty acids are potential mediators in gut inflammation”. Animal Nutrition 8 (2022): 350-360.
  18. Dolai S and Borody T. “Editorial: Prerequisites for a successful probiotic therapy in dysbiosis”. Journal of Gastrointestinal Infection 12 (2022): 83-85.
  19. Vergara DM and González SME. “Short chain fatty acids (butyric acid) and intestinal Diseases”. Nutrición Hospitalaria 4 (2017): 58-61.
  20. Gonçalves P., et al. “A cross-talk between microbiota-derived short-chain fatty acids and the host mucosal immune system regulates intestinal homeostasis and inflammatory bowel disease”. HAL Open Science Pasteur (2019): 02122775.
  21. den Besten G., et al. “The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism”. Journal of Lipid Research 9 (2013): 2325-2340.
  22. Aho VTE., et al. “Relationships of gut microbiota, Short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease”. Molecular Neurodegeneration 1 (2021): 6.
  23. Deleu S., et al. “Short chain fatty acids and its producing organisms: An overlooked therapy for IBD?”. EBioMedicine 66 (2021): 103293.
  24. De la Cuesta ZJ., et al. “Higher fecal short-chain fatty acid levels are associated with gut microbiome dysbiosis, obesity, hypertension and cardiometabolic disease risk factors”. Nutrients1 (2019): 51.
  25. Robles-Vera I., et al. “Probiotics prevent dysbiosis and the rise in blood pressure in genetic hypertension: role of short-chain fatty acids”. Molecular Nutrition6 (2020): 1900616.
  26. Holmes ZC., et al. “Short-chain fatty acid production by gut microbiota from children with obesity differs according to prebiotic choice and bacterial community composition”. mBio4 (2020): e00914-20.
  27. Prochazkova M., et al. “Vegan diet is associated with favorable effects on the metabolic performance of intestinal microbioma”. Frontiers in Nutrition 8 (2022): 783302.
  28. Yuille S., et al. “Live biotherapeutics-derived short-chain fatty acids as potent class I HDAC inhibitors”. Poster Number: 1011. Keystone Symposia. Abstracts Microbiome: The antimicrobial efficacy and phytochemical analysis of the stem bark of Azadirachta indica (Neem) (2019).
  29. Rodríguez-Carrio J., et al. “Intestinal dysbiosis is associated with altered short-chain fatty acids and serum-free fatty acids in systemic lupus erythematosus”. Frontiers in Immunology 8 (2017): 23.
  30. Niccolai E., et al. “Evaluation and comparison of short chain fatty acids composition in gut diseases”. World Journal of Gastroenterology 36 (2019): 5543-5558.
  31. Yao Y., et al. “Role of short-chain fatty acids in immunity, inflammation and metabolism”. Critical Review in Food Science and Nutrition1 (2022): 1-12.
  32. Selber-Hnatiw S., et al. “Metabolic networks of the human gut microbiota”. Microbiology2 (2020): 96-119.

Álvaro Zamudio Tiburcio., et al. “Short Chain Fatty Acids in Intestinal Dysbiosis".  11.2 (2024): 01-06.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net